NCT00003840View on ClinicalTrials.gov

DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 2000

Primary Completion Date

September 30, 2002

Study Completion Date

July 31, 2005

Conditions
Leukemia
Interventions
BIOLOGICAL

DTGM fusion protein

Trial Locations (1)

27157-1082

Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT00003840 - DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter